Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells
Therapies to prevent diabetes in particular the progressive loss of β-cell mass and function and/or to improve the dysregulated metabolism associated with diabetes are highly sought. The incretin-based therapy comprising GLP-1R agonists and DPP-4 inhibitors have represented a major focus of pharmaceutical R&D over the last decade. The incretin hormone GLP-1 has powerful antihyperglycemic effect through direct stimulation of insulin biosynthesis and secretion within the β-cells; it normalizes β-cell sensitivity to glucose, has an antiapoptotic role, stimulates β-cell proliferation and differentiation, and inhibits glucagon secretion. However, native GLP-1 therapy is inappropriate due to the rapid post-secretory inactivation by DPP-4. Therefore, incretin mimetics developed on the backbone of the GLP-1 or exendin-4 molecule have been developed to behave as GLP-1R agonists but to display improved stability and clinical efficacy. New formulations of incretins and their analogs based on micro- and nanomaterials (i.e., PEG, PLGA, chitosan, liposomes and silica) and innovative encapsulation strategies have emerged to achieve a better stability of the incretin, to improve its pharmacokinetic profile, to lower the administration frequency or to allow another administration route and to display fewer adverse effects. An important advantage of these formulations is that they can also be used at the targeted non-invasive imaging of the beta-cell mass. This review therefore focuses on the current state of these efforts as the next step in the therapeutic evolution of this class of antidiabetic drugs.
KeywordsMicroparticles Nanoparticles Incretins GLP-1 Beta-cell Diabetes
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study, formal consent is not required.
- 12.Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig 91(1):301–307. https://doi.org/10.1172/jci116186 PubMedPubMedCentralCrossRefGoogle Scholar
- 18.Nauck MA, Petrie JR, Sesti G et al (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39(2):231–241. https://doi.org/10.2337/dc15-0165 PubMedGoogle Scholar
- 24.DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P (2011) Encapsulation of exenatide in poly-(d, l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 13(11):1145–1154. https://doi.org/10.1089/dia.2011.0050 PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Nguyen HN, Wey SP, Juang JH et al (2011) The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 32(10):2673–2682. https://doi.org/10.1016/j.biomaterials.2010.12.044 PubMedCrossRefGoogle Scholar
- 51.Hassani LN, Lewis A, Richard J (2015) Oral peptide delivery: technology landscape and current status. On Drug Deliv 59:12–17Google Scholar
- 58.Zhang B, Yang B, Zhai C, Jiang B, Wu Y (2013) The role of exendin-4-conjugated superparamagnetic iron oxide nanoparticles in beta-cell-targeted MRI. Biomaterials 34(23):5843–5852. https://doi.org/10.1016/j.biomaterials.2013.04.021 PubMedCrossRefGoogle Scholar
- 63.Frias JP, Guja C, Hardy E et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004–1016. https://doi.org/10.1016/s2213-8587(16)30267-4 PubMedCrossRefGoogle Scholar
- 66.Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M (2015) Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Sci Rep 5:18039. https://doi.org/10.1038/srep18039
- 67.Yang PY, Zou H, Chao E, Sherwood L, Nunez V, Keeney M, Ghartey-Tagoe E, Ding Z, Quirino H, Luo X, Welzel G, Chen G, Singh P, Woods AK, Schultz PG, Shen W (2016) Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. Proceedings of the National Academy of Sciences of the United States of America 113(15):4140-4145. https://doi.org/10.1073/pnas.1601653113